Unraveling the silent consensus behind the GLP-1 gold rush...
On the surface, Novo Nordisk’s Q3 2025 earnings call read like a victory lap. Oral Wegovy hit 5 million prescriptions in six months—the fastest-selling drug in pharmaceutical history. Yet the stock tanked 6% that same day. The market wasn’t buying the narrative. Something beneath the headline numbers was bleeding.
Tracing the revenue trails in the obesity drug wars...
Let’s step back. The GLP-1 market is a two-player game: Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro). Together they command >90% of a $150 billion+ opportunity by 2030. But the narrative has shifted from “both win” to “zero-sum trench warfare.” The core question: Is Novo’s dominance sustainable, or is Lilly quietly engineering a regime change?
Diagnosing the fatal flaw in Novo’s ledger...
Novo’s CEO Lars Fruergaard Jørgensen admitted in a rare moment of candor: “Lilly has been more successful in volume growth and market share capture.” That’s damning. Since Zepbound’s launch in late 2023, Lilly has eroded Novo’s new-prescription share from ~60% to below 50% in the US. Oral Wegovy’s 5 million scripts are impressive, but they’re mostly “switch” patients—existing Wegovy injectable users moving to pills—not net new market expansion. The real yield is lower than the headline.
Meanwhile, Lilly’s oral small-molecule candidate, orforglipron, is in Phase III. If approved (2026-2027), it will be a game-changer: no cold chain, no injection, lower cost of goods. Novo’s SNAC absorption technology for oral semaglutide is a clever peptide trick, but it can’t compete with a true small molecule on manufacturing scale. The patent cliff for semaglutide (early 2030s) means Novo is racing to build a sticky patient base before the generics arrive. Lilly, with its diversified portfolio (only 60% GLP-1 exposure), can afford to play the long game.
Mapping the hidden narratives behind the price war...
Here’s the contrarian angle the market is missing: The real threat isn’t Lilly—it’s the payer. The Inflation Reduction Act (IRA) gives Medicare the power to negotiate drug prices for the first time. GLP-1 drugs are among the top Medicare Part D spenders. A 30-60% price cut by 2027 is baked into the consensus, but the market hasn’t fully priced the second-order effect: if Novo and Lilly compete on price to win formulary access, net prices could collapse faster than volume can compensate. Novo’s “price halved, volume doubled” arithmetic works only if volume doubles—and if the payer doesn’t demand a second price cut next year.
Exposing the root cause beneath the stock divergence...
Novo’s 6% drop on “good news” is a classic narrative trap. The market is re-rating Novo’s earnings quality. In 2024, Novo’s operating margin slipped from ~47% to ~42% due to pricing concessions and capacity investments. That’s a structural compression, not a blip. Lilly, by contrast, has maintained ~45% margins while gaining share. The difference? Lilly’s oncology and immunology franchises (Verzenio, Taltz) provide earnings ballast; Novo has almost nothing outside GLP-1. One bad trial readout (CagriSema missed expectations in Dec 2024, causing a 20% single-day drop) and the entire thesis wobbles.
Constructing the truth from fragmented data...
The 5 million oral Wegovy scripts—where did they come from? No independent third-party source (e.g., IQVIA) has confirmed the number. If 40% are discount-priced or patient-assistance, the net revenue per script is far lower than the $1,350 list price. And the 12-month persistence rate on GLP-1 drugs is only ~35%. Those 5 million scripts may represent only 1.5 million patients still on therapy after a year. The headline masks the attrition.
Turn the lens to China. Both companies are rushing to capture the 200 million obese population. But local competitors (Innovent’s mazdutide, Hengrui’s HRS9531) are coming with price tags 50-70% lower. The Chinese market will likely become a price war independent of the West—a drag on global margins that neither company has fully modeled.
Takeaway: The GLP-1 war is not a battle of efficacy—both drugs work. It’s a battle of narrative control. Novo owns the “first mover, oral convenience” story. Lilly owns the “best-in-class, diversified, lower-cost future” story. The market is betting on Lilly. But the real wildcard is the payer: if Medicare covers obesity drugs (CMS rule change expected 2025-2026), the entire market doubles overnight—and both companies win. Until then, trace the liquidity. Follow the scripts. Audit the narrative.
